UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 727

Sortiert nach

Accretion of the Earth and segregation of its core

Nature, 2006-06, Vol.441 (7095), p.825-833

2006

Volltextzugriff (PDF)

Exploring the wet granulation growth regime map – validating the boundary between nucleation and induction

Chemical engineering research & design, 2020-04, Vol.156, p.469-477

2020

Volltextzugriff (PDF)

The development of a growth regime map for a novel reverse-phase wet granulation process

International journal of pharmaceutics, 2016-10, Vol.512 (1), p.224-233

2016

Volltextzugriff (PDF)

Late Accretion on the Earliest Planetesimals Revealed by the Highly Siderophile Elements

Science (American Association for the Advancement of Science), 2012-04, Vol.336 (6077), p.72-75

2012

Volltextzugriff (PDF)

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9514-9514

2020

Volltextzugriff (PDF)

Tuning interfacial interactions for bottom‐up assembly of surface‐anchored metal‐organic frameworks to tailor film morphology and pattern surface features

Aggregate (Hoboken), 2022-08, Vol.3 (4), p.n/a

2022

Volltextzugriff (PDF)

An assessment of powder pycnometry as a means of determining granule porosity

Pharmaceutical development and technology, 2015-05, Vol.20 (3), p.257-265

2015

Volltextzugriff (PDF)

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3004-3004

2017

Volltextzugriff (PDF)

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3001-3001

2016

Volltextzugriff (PDF)

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8010-8010

2014

Volltextzugriff (PDF)

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2524-2524

2013

Volltextzugriff (PDF)

Formulation in a drop - Templated granulation and compaction analysis

Powder technology, 2024-04, Vol.438, p.119611, Article 119611

2024

Volltextzugriff (PDF)

Flow field analysis of a toroidal flow fluidized bed granulator

Chemical engineering research & design, 2024-08, Vol.208, p.359-368

2024

Volltextzugriff (PDF)

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2616-2616

2021

Volltextzugriff (PDF)

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

Journal of clinical oncology, 2020-06, Vol.38 (18_suppl), p.LBA5-LBA5

2020

Volltextzugriff (PDF)

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21682-e21682

2020

Volltextzugriff (PDF)

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS9084-TPS9084

2020

Volltextzugriff (PDF)

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9059-9059

2021

Volltextzugriff (PDF)

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9068-9068

2021

Volltextzugriff (PDF)

EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20525-e20525

2017

Volltextzugriff (PDF)

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9023-9023

2019

Volltextzugriff (PDF)

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3003-3003

2020

Volltextzugriff (PDF)

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8564-8564

2021

Volltextzugriff (PDF)

Phase I trial of in situ vaccination with autologous CCL21 -modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9135-TPS9135

2021

Volltextzugriff (PDF)

1 – 25 von 727

Suche als RSS-Feed

Aktive Filter

KollektionProject MUSE All Journals

PublikationsformBuchkapitel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(660)
Mit Volltextzugriff
(643)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(465)
Life Sciences & Biomedicine
(379)
Humans
(297)
Male
(150)
Female
(146)
Adult
(96)
Middle Aged
(94)
Aged
(79)
General & Internal Medicine
(60)
Biological And Medical Sciences
(59)
Animals
(53)
Patients
(51)
Neurosciences & Neurology
(46)
Treatment Outcome
(43)
Medical Sciences
(41)
Science & Technology - Other Topics
(41)
Physical Sciences
(40)
Surgery
(40)
Medicine, General & Internal
(39)
Multidisciplinary Sciences
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(87)
Plos One
(15)
Nature
(12)
Mmwr. Morbidity And Mortality Weekly Report
(10)
Morbidity And Mortality Weekly Report
(10)
Nature Communications
(9)
The New England Journal Of Medicine
(9)
Neurocritical Care
(8)
Bmj Open
(7)
Stroke
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Accretion of the Earth and segregation of its core

Exploring the wet granulation growth regime map – validating the boundary between nucleation and induction

The development of a growth regime map for a novel reverse-phase wet granulation process

Late Accretion on the Earliest Planetesimals Revealed by the Highly Siderophile Elements

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

Tuning interfacial interactions for bottom‐up assembly of surface‐anchored metal‐organic frameworks to tailor film morphology and pattern surface features

An assessment of powder pycnometry as a means of determining granule porosity

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M

Formulation in a drop - Templated granulation and compaction analysis

Flow field analysis of a toroidal flow fluidized bed granulator

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06)

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC)

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ)

Phase I trial of in situ vaccination with autologous CCL21 -modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Aktive Filter

Suchergebnisse filtern